MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
NCT04554836
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
6
Enrollment
OTHER
Sponsor class
Conditions
Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Interventions
DRUG:
Cetuximab
OTHER:
FOLFIRI
Sponsor
TheraOp